Clinical Trials Logo

Clinical Trial Summary

The few reports on effects of psychedelic substances on cerebral metabolic rate (CMRglc) indicate increases (psilocybin; human FDG-PET) or decreases (LSD, rat autoradiography; 5-MeO-DMT rat autoradiography). There are no reports of effects of DMT and/or harmine on cerebral energy metabolism. The primary objective of this study is thus to assess acute cerebrometabolic effects of harmine/DMT in healthy volunteers using quantitative FDG-PET, that is, to measure CMRglc before and after simultaneous treatment with an oral harmine and DMT formulation developed (and already applied) by the investigators' project partners at the University of Zurich. As a secondary objective, the researchers aim to correlate the time-dependent effects on CMRglc as assessed in the PET images with the time-dependent self-reported intensity of participants' psychedelic experience.


Clinical Trial Description

n/a


Study Design


NCT number NCT06252506
Study type Interventional
Source Insel Gruppe AG, University Hospital Bern
Contact Paul K Cumming, PhD
Phone +41 79 4813163
Email paul.cumming@insel.ch
Status Recruiting
Phase Phase 1
Start date January 22, 2024
Completion date April 2025